^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TMPRSS11E (Transmembrane Serine Protease 11E)

    i
    Other names: TMPRSS11E, Transmembrane Serine Protease 11E, DESC1, TMPRSS11E2, Transmembrane Protease, Serine 11E, Transmembrane Protease Serine 11E2, Transmembrane Protease Serine 11E, Serine Protease DESC1, Transmembrane Protease, Serine 11E2
    10ms
    Identification and Validation of Amino Acid Metabolism-Related Biomarkers and Investigation of their Potential Mechanisms in Lung Adenocarcinoma. (PubMed, Curr Gene Ther)
    The five identified AAMRGs in LUAD were validated and appropriately utilized to construct a risk assessment model that could potentially act as prognostic biomarkers for LUAD patients.
    Journal
    |
    SLC34A2 (Solute carrier family 34 member 2) • TMPRSS11E (Transmembrane Serine Protease 11E) • HTRA1 (HtrA Serine Peptidase 1)
    over2years
    And-Gate CAR T-Cells to Improve Tumour Specificity and Targeting of Low-Expression Antigens in Multiple Myeloma (ASH 2023)
    In summary, our work suggests that AND-gate targeting can increase not just specificity, but potency, even against very low expression tumour targets in MM. Link to preprint https://doi.org/10.1101/2023.04.04.535580
    CAR T-Cell Therapy • IO biomarker
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • TMPRSS11E (Transmembrane Serine Protease 11E) • HTRA1 (HtrA Serine Peptidase 1)
    |
    TNFRSF8 expression • IFNG expression • IL2 expression • TMPRSS11E expression
    over2years
    Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis. (PubMed, Front Immunol)
    Immune cell markers are effective in clustering LUAD samples into different subtypes, and they play important roles in regulating the immune microenvironment and cancer development. In addition, the seven-gene risk model may serve as a guide for assisting in personalized treatment in LUAD patients.
    Journal • Gene Signature • IO biomarker • Machine learning
    |
    MELTF (Melanotransferrin) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CPA3 (Carboxypeptidase A3) • TMPRSS11E (Transmembrane Serine Protease 11E) • HTRA1 (HtrA Serine Peptidase 1) • S100P (S100 calcium binding protein P)
    over2years
    Construction of a genomic instability-derived predictive prognostic signature for non-small cell lung cancer patients. (PubMed, Cancer Genet)
    The GI related 13-gene signature (TMPRSS11E, TNNC2, HLF, FOXM1, PKMYT1, TCN1, RGS20, SYT8, CD1B, LY6K, MFSD4A, KLRG2 APCDD1L) could reliably predict the prognosis of NSCLC patients.
    Journal
    |
    FOXM1 (Forkhead Box M1) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1) • TMPRSS11E (Transmembrane Serine Protease 11E) • HTRA1 (HtrA Serine Peptidase 1)
    almost3years
    DNA methylation and mutation spectrum among pediatric acute lymphoblastic leukemia patients by Hispanic/Latinx ethnicity (AACR 2023)
    Few of the candidate genes observed in HSP (ITPA, MBP, PPP4R12, and SPOCK3) have been previously implicated in leukemia. The findings suggest that the methylation signatures and mutation spectrum for HSP and NHW pediatric acute ALL patients might differ and further studies among HSP, a group with the highest prevalence of acute pediatric ALL, could potentially identify new genetic and epigenetic markers for acute pediatric ALL.
    Clinical • Epigenetic controller
    |
    KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • JARID2 (Jumonji And AT-Rich Interaction Domain Containing 2) • TMPRSS11E (Transmembrane Serine Protease 11E) • YTHDC1 (YTH Domain Containing 1) • GSTT1 (Glutathione S-transferase theta 1) • HTRA1 (HtrA Serine Peptidase 1) • ITPA (Inosine Triphosphatase) • RPS16 (Ribosomal Protein S16) • TEX26 (Testis Expressed 26) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    NRAS mutation
    over3years
    Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma (ASH 2022)
    We have previously shown that it is possible to select rationally between bortezomib- and lenalidomide-based therapy using a gene expression signature. Conclusions By combining transcriptomic and proteomic approaches, we have generated a panel of six cell surface proteins that are amenable to flow cytometry and can predict carfilzomib-responsiveness. Prospective validation of these markers is underway.
    IO biomarker
    |
    CD27 (CD27 Molecule) • CLEC7A (C-Type Lectin Domain Containing 7A) • GPR176 (G Protein-Coupled Receptor 176) • TMPRSS11E (Transmembrane Serine Protease 11E) • HTRA1 (HtrA Serine Peptidase 1)
    |
    lenalidomide • bortezomib • carfilzomib